Aranesp ``145 Study'' Shows No Difference in Survival in Patients
with Small-Cell Lung Cancer
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amgen(NASDAQ: AMGN) today announced the results of the "145 study", arandomized, double-blind, placebo-controlled, multicenter Phase 3study of
Aranesp(R) (darbepoetin alfa) in 600 previously untreatedpatients with extensive-stage small-cell lung cancer (SCLC)receiving platinum-containing chemotherapy. The study demonstratedno statistica...
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving
Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual
Meeting
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - Amgen(Nasdaq:AMGN) today presented the results from a randomized,double-blind, placebo-controlled Phase 3 study evaluating theefficacy and safety of
Aranesp(R) (darbepoetin alfa) for thetreatment of anemia in patients with active cancer not receivingchemotherapy or radiotherapy ("the 103 study").
Aranesp is notapproved for use by the FD...